GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.

Autor: Reiswich V; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Schmidt CE; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Lennartz M; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Höflmayer D; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Hube-Magg C; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Weidemann S; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Fraune C; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Büscheck F; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Möller K; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bernreuther C; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Simon R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Clauditz TS; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Blessin NC; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bady E; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Sauter G; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Uhlig R; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Steurer S; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Minner S; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Burandt E; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Dum D; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Marx AH; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Department of Pathology, Academic Hospital Fuerth, Fuerth, Germany., Krech T; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany., Lebok P; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.; Institute of Pathology, Clinical Center Osnabrueck, Osnabrueck, Germany., Hinsch A; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Jacobsen F; Institute of Pathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jazyk: angličtina
Zdroj: Pathobiology : journal of immunopathology, molecular and cellular biology [Pathobiology] 2023; Vol. 90 (4), pp. 219-232. Date of Electronic Publication: 2023 Jan 17.
DOI: 10.1159/000527382
Abstrakt: Introduction: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.
Methods: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.
Results: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).
Conclusion: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.
(© 2023 S. Karger AG, Basel.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje